Johnson & Johnson’s drug for treatment-resistant depression got off to a slow start when it launched in 2019, but strong sales growth has put it on a blockbuster trajectory this year. 

When loss-making biotech companies mix debt with sluggish sales, difficult options like restructuring and asset sales remain.

Grey Wolf Therapeutics has secured $99m via an expanded series B financing to advance its antigen modulation approach in cancer and to further explore its use in autoimmune disease indications.

Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline.